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Purpose
LS can cause significant morbidity in the growing child,
including joint contractures and facial and extremity
hemiatrophy. Optimal therapy is not known, and few
randomized clinical trials have been carried out. A prior
survey of Childhood Arthritis and Rheumatology
Research Alliance (CARRA) members identified metho-
trexate (MTX) and corticosteroids (CS) as the most
commonly used medications to treat serious jLS. How-
ever, there was no consensus on dose, route of adminis-
tration, or duration of treatment for these medications.
Objective: To develop standardized consensus treatment
regimens and disease assessments tools for jLS.
Methods
A core group of pediatric rheumatologists based in
CARRA was formed to evaluate and develop standar-
dized jLS regimens and assessments. Two dermatolo-
gists who study jLS and a lay person were also
recruited. Members reviewed literature on current treat-
ments and assessments, and through surveys and Delphi
processes, developed criteria to define different levels of
disease severity, generated consensus regimens for jLS
treatment, and agreed upon clinical parameters to evalu-
ate disease activity and damage. Preliminary regimens
and assessments were discussed with the CARRA mem-
bership, and modified based on feedback.
Results
We have developed criteria to define high, moderate,
and low disease severity, and standardized clinical activ-
ity and damage assessments for jLS. An atlas of lesion
images was generated to facilitate scoring the level of
several parameters (erythema, hyperpigmentation, hypo-
pigmentation, dermal atrophy, and subcutaneous tissue
loss). See table 1.
Through use of the Delphi process, the jLS core group
was able to generate consensus initial treatment regi-
mens for MTX, MTX with oral CS, and MTX with
intravenous CS, including a general tapering regimen for
oral corticosteroids. Table 2.
Conclusion
There is a need for standardized jLS disease assessments
and treatment regimens to be able to compare treat-
ment efficacy. A CARRA subgroup has developed con-
sensus assessments and treatment regimens for jLS. The
efficacy of these regimens will be evaluated in future
comparative effectiveness studies.
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Table 1 Parameters are scored for each involved anatomic site
Clinical Activity Parameters: Clinical Damage Parameters:
Scoring levels Scoring levels
Erthema: 0 to 3 Dermal atrophy: None, shiny, visible vessel, cliff-drop
Violaceous color: None, lilac ring, viol. Center Subcutaneous tissue atrophy: 0 to 3
Development in lesion size: Yes/no Hyperpigmentation: 0 to 3
Change in lesion size: Smaller, stable, larger Hypopigmentation: 0 to 3
Skin induration: lesion edge: 0 to 3 Skin thickness: lesion center: 0 to 3
Lesion warmth: Yes/no
Distinct margin: None, erythematous, hyperpigmented margin
Table 2
Regimen
MTX alone MTX + CS MTX + IV CS
MTX weekly dose 1 mg/kg SQ (max 25 mg) 1 mg.kg SQ (max 25 mg) 1 mg.kg SQ (max 25 mg)
Initial CS dose, duration None 2 mg/kg/day (max 60 mg) divided bid 30 mg/kg/dpse (max 1 gm)
Duration: at least 2 weeks Either: 3 consecutive daily doses per month
OR 1 dose per week
Duration: 3 months
CS taper targets None Down to: None
1 mg/kg/d (max 30 mg) by end of 2 months
0.5 mg/kg/d (max 15 mg) by end of 4 months
0.25 mg/kg/d (max 7.5 mg) by end of 6 months
Off CS by end of 48 weeks
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